Ranibizumab
Amino Acids, Peptides, and Proteins
Proteins
Blood Proteins
Immunoproteins
Immunoglobulins
Antibodies
1 articolo — 2014-2014
RI
Editoriali
Il caso di Avastin e Lucentis: big-pharma vs agenzie regolatorie
F. Marchetti
2014/3 — pag. 143-145
Argomenti correlati
Conflict of Interest (33)
Drug Industry (32)
Drug Approval (22)
Drug Costs (17)
diabetic retinopathy (4)
agenzie regolatorie (3)
Bevacizumab (3)
regulatory agencies (3)
retinopatia diabetica (3)
Macular Degeneration (2)
conflitto (2)
conflict (2)
big pharma (2)
age-related macular degeneration (AMD) (1)
Lucentis (1)
ranibizumab (Lucentis) (1)
maculopatia degenerativa (1)
fraud, collusion and financial disaster (1)
Avastin (1)
bevacizumab (Avastin) (1)
